kOe 224 7 8
FDA 510K Summary of Safety and Effectiveness for
EVIS MD PLATINUM RED LIGHT THERAPY
1. General Information
Submitter: Ageless Beauty Corporation
28470 Avenue Stanford
Suite 350
Valencia, CA 91355
Office: +1 877 629-4429
Fax: +1 661 295-5088
Contact Person: C/O Jill Creasy
Aesthetica-Tech
675 Pine Street
Elgin, IL 60123
847-429-963]
contact@aestheticatech.com
Summary Preparation Date: August 6, 2008
2. Device Name
Device Name: Evis MD Platinum Red Light Therapy
Classification Name: Laser Surgical instrument for use in General, Plastic Surgery
and in Dermatology
Although this device is not a laser, the specifications
developer feels this is the closest applicable classification
name.
Regulation Number 21 CER 878.4810
Regulatory Class ul
Product Code GEX
3. Predicate Device
The Evis MD Platinum Light Therapy device is substantially equivalent to the Omnilux Revive (K030426),
4. Device Description
‘The Evis MD Platinum Red Light Therapy device that utilizes Light Emitting Diodes to provide LED light
to the body. The hand held device contains the power supplies and a built in audible indicator with auto
shut off. The device delivers the tight to the skin as it moves over the skin. The wavelength for red is 630
+/- 5 nanometer. Evis MD Platinum Red does not use any software.
5. Intended Use and Indications:
The Evis MD Platinum Red Light Therapy is intended to provide light to the body.
Generally indicated for dermatology use for the treatment of superficial, benign vascular and
pigmented lesions “such as but not limited to solar lentigines, sun spots, liver spots and age
spots".

kog7297

6. Comparison of Technological Differences:
The intended use and technological characteristics of the Evis MD Platinum Red system is virtually
identical to the intended use and technological characteristics of the listed equivalent device. Any
differences between the Evis MD Platinum Red and the equivalent device have no significant influence on
safety or effectiveness of the Evis product.

7. Nonclinical Performance Data
The Evis MD Platinum Red was tested and complics with Electrical Safety and EMC testing, which include
the requirements of IEC/EN/UL 60601-1 “Medical Electrical Equipment Part 1 — General Requirements for
Safety” and was tested in accordance to Medical Directive 93/42/EEC - CSA 601.1, EMC Directive
2004/108/EC IEC/EN 60601-1-2 “Medical Electrical Equipment Part 1-2, General Requirements for Safety
— Collateral Standard Electromagnetic Compatibility Requirements and Tests. FCC 47CRF PT 18
Industrial, Scientific, and Medical Equipment. [CES 005 Radio Frequency Light Device

8. Conclusions
Based upon an analysis of the overall performance characteristics for the Evis MD Platinum Red Light
Therapy, Ageless Beauty Corporation believes that no significant differences exist between this system
and the predicate systems quoted, therefore, the Evis MD Platinum Red Light Therapy device does not
impose any new safety or effectiveness concerns.

2 ¢ DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
hives Food and Drug Administration
9200 Corporate Boulevard
OCT 08 2008 Rockville MD 20850
Ageless Beauty Corporation
Yo Aesthetica-Tech
Ms. Jill Creasy ‘
675 Pine Street
Elgin, Illinois 60123
Re: K082247
Trade/Device Name: Evis MD Platinum Red Light Therapy
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery and
in dermatology
Regulatory Class: II
Product Code: GEX
Dated: September 19, 2008
Received: September 22, 2008
Dear Ms. Creasy:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class II] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register. .
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

Page 2 — Ms. Jill Creasy
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050,
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance at
(240) 276-0115. Also, please note the regulation entitled, “Misbranding by reference to
premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance,
please contact CDRH’s Office of Surveillance and Biometric’s (OSB’s) Division of Postmarket
Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events
(Medical Device Reporting (MDR)), ‘please contact the Division of Surveillance Systems
at (240) 276-3464. You may obtain other general information on your responsibilities under the
Act from the Division of Small Manufacturers, International and Consumer Assistance
at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address
http://www. fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Director

Division of General, Restorative

and Neurological Devices
Office of Device Evaluation
Center for Devices and :
Radiological Health

Enclosure

Indications for Use
510(k) Number (if known): __ 082247
Device Name: Evis MD Platinum Red Light Therapy
Indications for Use:
The Evis MD Platinum Red Light Therapy device is intended to provide light to the body.
Generally indicated to dermatology use for the treatment of superficial, benign vascular and
pigmented lesions “such as bul not limited to solar lentigines, sun spots, liver spots and age
spots",
Prescription Use X AND/OR Over-The-Counter Use
(21 CFR Part 801 Subpart D) (21 CFR Part 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE
IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Sf. .
TL AP ade Farm os
(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices
‘ Page lof 1__
510(k) Number__K OS 2247

